ATE238058T1 - Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel - Google Patents

Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel

Info

Publication number
ATE238058T1
ATE238058T1 AT96936018T AT96936018T ATE238058T1 AT E238058 T1 ATE238058 T1 AT E238058T1 AT 96936018 T AT96936018 T AT 96936018T AT 96936018 T AT96936018 T AT 96936018T AT E238058 T1 ATE238058 T1 AT E238058T1
Authority
AT
Austria
Prior art keywords
benzenesulfonamides
inflammatory agents
veterinary use
substituted pyrazolyl
pyrazolyl
Prior art date
Application number
AT96936018T
Other languages
German (de)
English (en)
Inventor
Peter C Isakson
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24138015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE238058(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE238058T1 publication Critical patent/ATE238058T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96936018T 1995-09-29 1996-09-27 Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel ATE238058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,318 US5756529A (en) 1995-09-29 1995-09-29 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
PCT/US1996/015538 WO1997011704A1 (en) 1995-09-29 1996-09-27 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents

Publications (1)

Publication Number Publication Date
ATE238058T1 true ATE238058T1 (de) 2003-05-15

Family

ID=24138015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96936018T ATE238058T1 (de) 1995-09-29 1996-09-27 Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel

Country Status (21)

Country Link
US (1) US5756529A (cs)
EP (1) EP0854723B1 (cs)
JP (1) JPH11514991A (cs)
KR (1) KR100498730B1 (cs)
CN (1) CN1202828A (cs)
AT (1) ATE238058T1 (cs)
AU (1) AU718300B2 (cs)
BR (1) BR9610974A (cs)
CA (1) CA2233620C (cs)
CZ (1) CZ297183B6 (cs)
DE (1) DE69627683T2 (cs)
DK (1) DK0854723T3 (cs)
ES (1) ES2197954T3 (cs)
IL (1) IL123635A (cs)
NO (1) NO321157B1 (cs)
NZ (1) NZ320919A (cs)
PL (1) PL191934B1 (cs)
PT (1) PT854723E (cs)
RO (1) RO120408B1 (cs)
RU (1) RU2253456C2 (cs)
WO (1) WO1997011704A1 (cs)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
CA2223154A1 (en) * 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) * 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CA2363590A1 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
WO2000076503A1 (en) 1999-06-16 2000-12-21 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
HK1052701A1 (zh) * 1999-12-03 2003-09-26 辉瑞产品公司 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
ATE252576T1 (de) 1999-12-03 2003-11-15 Pfizer Prod Inc Heteroarylphenylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
DE60004001T2 (de) * 1999-12-03 2004-04-15 Pfizer Products Inc., Groton Acetylenderivate zur Verwendung als schmerzstillendes oder entzündungshemmendes Mittel
CN1216869C (zh) * 1999-12-08 2005-08-31 药品公司 赛利可喜的多态晶型
IL144760A0 (en) * 1999-12-08 2002-06-30 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
AU780774C (en) * 1999-12-22 2006-09-21 Pharmacia Corporation Dual-release compositions of a cyclooxygenase-2-inhibitor
WO2001078723A1 (en) * 2000-04-12 2001-10-25 Smithkline Beecham Corporation Compounds and methods
AU2001251650A1 (en) * 2000-04-18 2001-10-30 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
AU2001253749A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
DE60204823T2 (de) 2001-07-05 2005-12-29 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
MXPA04002682A (es) * 2001-09-19 2004-06-18 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
US6956052B2 (en) 2001-09-19 2005-10-18 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037335A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
BR0213763A (pt) 2001-11-02 2004-10-19 Pfizer Prod Inc Sìntese eficiente de pirazóis contendo um heteroátomo -5
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
US7026346B2 (en) * 2002-04-08 2006-04-11 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
CA2492066A1 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
RU2325189C2 (ru) * 2003-03-20 2008-05-27 Фармация Корпорейшн Способ и фармацевтическая композиция для доставки противовоспалительного средства
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
PL1745791T3 (pl) 2003-05-07 2013-11-29 Osteologix As Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US7659426B2 (en) * 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
CA2675510A1 (en) * 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and oxidative stress in mammals
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
RU2406505C2 (ru) * 2007-06-29 2010-12-20 Федеральное государственное образовательное учреждение высшего профессионального образования "САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ АКАДЕМИЯ ВЕТЕРИНАРНОЙ МЕДИЦИНЫ" (ФГОУ ВПО СПГАВМ) Способ лечения воспалительного заболевания пясти и плюсны у собак
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
CN103443092B (zh) * 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CN103242233B (zh) * 2012-02-08 2014-07-30 北京博爱汇康医药科技有限责任公司 制备塞来昔布的新方法
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
HK1214252A1 (zh) 2013-03-15 2016-07-22 Verseon Corporation 作為凝血酶抑制劑的鹵代吡唑
NZ711064A (en) 2013-03-15 2019-06-28 Verseon Corp Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CN107686465B (zh) * 2017-09-02 2020-10-27 东北农业大学 地拉考昔的制备方法
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
ATE233245T1 (de) * 1993-11-30 2003-03-15 Searle & Co Substituierte pyrazolyl-benzolsulfonamide und ihre verwendung als cyclooxygenaseii inhibitoren
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation

Also Published As

Publication number Publication date
CA2233620A1 (en) 1997-04-03
CZ89798A3 (cs) 1999-04-14
AU718300B2 (en) 2000-04-13
EP0854723A1 (en) 1998-07-29
NZ320919A (en) 1999-10-28
WO1997011704A1 (en) 1997-04-03
AU7376896A (en) 1997-04-17
CN1202828A (zh) 1998-12-23
CZ297183B6 (cs) 2006-09-13
DE69627683D1 (de) 2003-05-28
US5756529A (en) 1998-05-26
NO981392D0 (no) 1998-03-27
KR19990063874A (ko) 1999-07-26
CA2233620C (en) 2011-11-22
PT854723E (pt) 2003-08-29
EP0854723B1 (en) 2003-04-23
PL191934B1 (pl) 2006-07-31
RO120408B1 (ro) 2006-01-30
DE69627683T2 (de) 2003-12-18
NO321157B1 (no) 2006-03-27
RU2253456C2 (ru) 2005-06-10
KR100498730B1 (ko) 2005-09-09
DK0854723T3 (da) 2003-08-11
ES2197954T3 (es) 2004-01-16
IL123635A (en) 2003-06-24
NO981392L (no) 1998-05-25
JPH11514991A (ja) 1999-12-21
BR9610974A (pt) 1999-07-13
PL325952A1 (en) 1998-08-17
IL123635A0 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
ATE238058T1 (de) Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel
PT946507E (pt) Compostos de pirrolilo substituidos para o tratamento da inflamacao
ATE301457T1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
DK0880350T3 (da) Behandling af dissemineret sklerose
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
GR3035438T3 (en) Compositions containing hydroperoxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
MY119711A (en) Method of inhibiting photoaging of skin
FR2810539B1 (fr) Procede et dispositif de traitement,notamment de maquillage, de coloration ou de soin cosmetique,de parties ou de la totalite du corps humain ou animal
YU58394A (en) Use of inhibitors of 5-alfa reductaze in the production of medicament used for the treatment of androgen alopecia
BR9407824A (pt) Processos para tratar e para interromper e reverter alopécia androgência e para diminuir o nível de 5 &-di-hidro-testosterona no escalpo humano
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
ATE178201T1 (de) Alkoholisches feuchtigkeitsspendendes after shave lotion
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
DE69628287D1 (de) Mittel zur behandlung lichtgeschädigter haut die einen rar-alpha antagonisten und ein multiselektives retinoid enthalten
NO20002649D0 (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
FR2751541B1 (fr) Composition dermo-cosmetique contenant un alcaloide du quinquina et methode de traitement cosmetique de l'alopecie
ATE234614T1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
NO950925D0 (no) Preparat og fremgangsmåte for behandling av hårtap
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
RU94024337A (ru) Антиметастатическое средство
ES2099613T3 (es) Empleo de hidroxinaftalinas en agentes colorantes.
NO954115L (no) Anvendelse av ceruletid-dietylaminsalt ved behandling av psoriasis
DE69637416D1 (de) Topische anwendung von opioiden, wie morphin, zur linderung von juckreiz und hautkrankheiten sowie hautreizungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0854723

Country of ref document: EP